Background
==========

Hand, foot, and mouth disease (HFMD) is a common infection caused by a number of viruses, commonly from the *Picornaviridae* family, and notably Enterovirus 71 (EV71), coxsackie A6 (CA6) and coxsackie A16 (CA16) ([@B154]; [@B88]). HFMD predominantly affects young children, however, older children and adults can also be affected ([@B107]; [@B124]). The main symptoms of the disease are fever, and blisters on the hands, feet, and mouth. Other usual clinical signs of HFMD include, nausea, vomiting, sore throat, fatigue, malaise, loss of appetite, and irritability. About 3 to 5 days after exposure to the virus, flat, red, or discolored bumps appear, almost rash-like, on the skin around the hands, feet mouth and buttocks of the patient. These can often blister and become vesicular sores ([@B14]). This rash is rarely itchy for infants, but it can be extremely itchy for an adult with the disease. The disease, whilst quite infectious, is normally self-limiting and symptoms usually disappear 7 to 10 days after disease onset (**Figure [1](#F1){ref-type="fig"}**; [@B14],[@B15]; [@B11]; [@B93]; [@B125]; [@B132]). Although HFMD is typically a mild illness, severe complications can sometimes occur. These include encephalitis, meningitis, acute flaccid paralysis, cardiorespiratory failure and can be fatal (**Figure [1](#F1){ref-type="fig"}**; [@B30]).
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The coverage of HFMD, with the exception of Polar regions, is global in distribution ([@B34]; [@B6]; [@B10]; [@B140]; [@B118]; [@B8]; [@B36]; [@B96]; [@B59]; [@B91]). The disease is most prevalent in the Asian--Pacific region where it has been endemic since the 1990's; and has subsequently caused large-scale epidemics every few years ([@B48]; [@B64]; [@B92]; [@B40]; [@B81]; [@B140]; [@B122]; [@B63]; [@B150]; [@B135]). Unfortunately, there are no specific anti-viral treatments for any of the viruses that cause HFMD. Therefore the treatment strategies for mild HFMD consist of palliative care including rehydration, analgesics for painful blisters and anti-inflammatories to reduce swelling ([@B146]; [@B108]; [@B145]). There is also no specific treatment of more severe HFMD that can be complicated by cardiorespiratory collapse. Key treatments are mechanical ventilation and inotropic support. Empirical treatments such as IVIG and continuous renal replacement therapy have been used in recent Asian outbreaks, but there are largely anecdotal ([@B146]; [@B108]).

Epidemiology and Spread
=======================

Hand, foot, and mouth disease usually affects children between the ages of 6 months to 5 years old, as this is the time when they no longer receive the benefits of passively transferred maternal antibodies. These antibodies can aid in protecting them from the etiological agents, i.e., EV71 that cause the disease, when their own immune system is not fully developed to fight the virus on its own ([@B42]). After the first encounter with the virus the child should start producing antibodies against the viral agent. These antibodies may offer a cross protective effect the next time the child encounters a HFMD causing virus ([@B97]; [@B52]; [@B162]).

The main etiological agents of HFMD are the coxsackievirus A16 (CA16) and Enterovirus 71 (EV71), both of which are from the *Enterovirus A* species of the Enterovirus genus of the *Picornaviridae* family ([@B1]; [@B137]; [@B168]). Other viruses such as coxsackie A5, A6, A9, A10, B2, and B5 have also been reported to cause the disease ([@B37]; [@B55]; [@B82]; [@B3]; [@B50]; [@B36]; [@B2]). Of the two main etiological agents that cause HFMD, only EV71 leads to neurological complications. (**Figure [1](#F1){ref-type="fig"}**; [@B64]; [@B146]; [@B93]). Since the almost total eradication of poliovirus, EV71 has become the most important neurotropic *Enterovirus* in the world. However, there is still much that is unknown about the interactions of this virus and more studies are required in this area to fully unravel the complete mechanism of EV71 ([@B78]; [@B51]).

Enterovirus 71 has been found all over the world with different symptoms and clinical manifestations seen during different outbreaks. The virus was first isolated in California, United States in 1969 from patients suffering from central nervous system (CNS) infections with cutaneous signs ([@B123]). EV71 was next seen in Europe, in Bulgaria and Hungary where patients suffered from CNS infections with cardiorespiratory failure and acute flaccid paralysis ([@B27]; [@B102]). EV71 was also starting too been seen in Asia at this time, with Japan reporting outbreaks of HFMD and CNS infections caused by EV71 ([@B44]; [@B57]). In 1997 an outbreak of EV71 presenting with HFMD, cutaneous infections, CNS infections, cardiorespiratory collapse and sudden death was reported in Malaysia ([@B90]; [@B11]). Since then, outbreaks and epidemics of EV71 with these clinical manifestations have become endemic to the Asian--Pacific region ([@B48]; [@B64]; [@B92]; [@B40]; [@B81]; [@B140]; [@B122]; [@B63]; [@B150]; [@B135]).

This protracted epidemic has drawn specific scientific interest. These outbreaks, with their larger variety of symptoms have drawn more questions that need answering about EV71 and its pathophysiology.

Biology of EV71
===============

Genome Organization
-------------------

Enterovirus 71 is a positive sense RNA virus, with a genome approximately 7.4 kb long with one open reading frame coding for the 4 structural (VP1-4) and 7 non-structural proteins (2A-C and 3A-D) ([@B9]). The genome is initially translated as a single polyprotein, which is then cleaved into the three cleavage intermediates P1, P2, and P3 (**Figure [2](#F2){ref-type="fig"}**). P1 is cleaved into VP3, VP1, and VP0 (which is then in turn cleaved to form VP4 and VP2). The VP1, VP2, and VP3 proteins form a surface pentameric subunit together with the VP4 protein, attached to the inner surface (**Figure [2](#F2){ref-type="fig"}**). The capsid is formed by a quasi-*T* = 3 symmetry of 60 copies of this subunit to form an icosahedral capsid ([@B115]). P2 is cleaved to form the viral protease 2A, and the 2BC polyprotein, which is then further cleaved in to the two non-structural proteins 2B and 2C. P3 is initially cleaved into 3AB and 3CD, and then further proteolysed to form the 3A, 3B, 3C, and 3D proteins (**Figure [2](#F2){ref-type="fig"}**; [@B94]).

![The genomic and molecular make up of the EV71 genome. **(A)** Diagram showing the EV71 genome, polyprotein and protein products produced during EV71 replication, size in base pairs (bp) also show. **(B)** Picture representation of the *T* = 3 structure of the VP1-3 structural genes of the EV71 capsid.](fmicb-08-02249-g002){#F2}

EV71 has been divided in to 6 genogroups, A, B, C, D, E, and F. The genogroups B and C can be further divided into the sub-genogroups B0--B5 and C1--C5. These genotypes were identified through genetic analysis of the VP1 gene ([@B137]). All of the genogroups of EV71 have an amino acid (aa) sequence similarity of over 90% to the virus genogroup A prototype BrCr strain; with *B* \> 92.2%; *C* \> 91.9%; *D* = 95.2%; *E* \> 93.6% and *F* \> 93.6% ([@B7]). They also have a high amino acid sequence similarity within the subgenogroups individually, with *A* \> 94.9%; *B* \> 95.9%; *C* \> 94.2%; *E* = 96.9% and *F* = 96.9% (information on D not available) ([@B7]). While the B and C subgroups have a global distribution, D, and E and F are restricted to India and Africa, respectively ([@B7]). Further phylogenetic analysis and Bayesian relaxed molecular clock method experiments suggests than EV71 originally emerged from CA16 around 1941 ([@B137]).

Virus Life Cycle
----------------

As humans are the only known hosts of EV71, all transmission is assumed to be human-to-human. The virus can survive on external surfaces for up to 3 days, so direct human-to-human contact is not always necessary as the virus can be picked up from these contaminated areas ([@B109]). The main route of transmission is through the fecal-oral route ([@B109]), however, it can also be spread through contact with virally contaminated vesicular fluid, surfaces, fomites and oral secretions as well as respiratory droplets (**Figure [1](#F1){ref-type="fig"}**; [@B131]). EV71 has been also found in fecal samples of symptomatic patients up to 75 days after infection, and up to 14 days in the throat ([@B28]).

Evidence suggests that the initial phase of replication occurs in lymphoid tissues of the tonsillar crypt ([@B46]) and in the Peyer's patches of the small intestine (**Figure [1](#F1){ref-type="fig"}**; [@B109]). The virus undergoes further replication in the adjacent lymph nodes (cervical and mesenteric lymph nodes, respectively) and this often leads to a mild viremia ([@B24]). In the majority of patients, viral infection is controlled at this point and the patients remain asymptomatic ([@B67]). However, if the viral infection is not controlled, the virus will then reaches high titres, and disseminate to the skin and mucous membranes to cause HFMD. In a small proportion of patients, EV71 can also enter the CNS and cause severe complications (**Figure [1](#F1){ref-type="fig"}**; [@B131]).

It has been noted that children who had detectable viraemia after 3 days had significantly more severe complications (**Figure [1](#F1){ref-type="fig"}**; [@B24]). Retrograde axonal transport has been proposed as the method of entry to the brain and CNS for EV71, as when mice were inoculated at the hind limbs with EV71 the virus appeared to be spread from the lower to the upper spine ([@B18]). However, with many receptors for EV71, including one on lymphocytes ([@B103]) retrograde axonal transport may not be the only mode of entry. After gaining entry to the brain and CNS, EV71 causes neuronal and astrocytic cell death (**Figure [1](#F1){ref-type="fig"}**; [@B16], [@B13]), which in turn leads to the CNS immune and inflammatory response and brainstem encephalitis (**Figure [1](#F1){ref-type="fig"}**; [@B13]). This leads to the mass release of certain cytokines, known as a cytokine storm ([@B80]). There have been many cytokines implicated in EV71 brainstem encephalitis which have been reported to be significantly increased in patients that suffer from pulmonary oedema. These include IL-1β, IL-1RA, G-CSF ([@B43]), IL-6, IL-10, TNF-αα and IFN-γ (**Figure [1](#F1){ref-type="fig"}**; [@B79], [@B80]; [@B157]). The destruction of the brainstem during EV71 infection, including the vasomotor and respiratory centers leads to a surge of catecholamines and autonomic dysfunction ([@B144]; [@B58]), which may be the cause of cardiorespiratory problems (**Figure [1](#F1){ref-type="fig"}**). It is currently unknown what is the exact cause of cardiac failure and pulmonary oedema but is thought to be a combination of these elements, cytokine storm and brainstem destruction.

Host Receptors
--------------

At least five molecules have been identified as possible cell surface receptors for EV71. Scavenger receptor B2 (SCARB2) ([@B153]), P-selectin glycoprotein ligand-1 (PSGL-1) ([@B103]), sialylated glycan ([@B155]), heparan sulfate ([@B134]) and annexin II (Anx2) ([@B156]) have been reported to act, individually, as receptors for EV71. The most characterized of these five are scavenger receptor class B member 2 (SCARB2) and PSGL-1 ([@B103]; [@B151]). SCARB2 (also known as LIMP-2) is a highly abundant protein found in the lysosomal membrane, which participates in the reorganization and membrane transport of the endosomal/lysosomal compartment. SCARB2 can acts as a receptor for all strains of EV71 and is considered the critical receptor for infection ([@B152]). PSGL-1, which is primarily expressed on the surface of leukocytes, is involved in leukocyte rolling/interacting with the vascular endothelium in the early stages of inflammation ([@B47]). A post translational modification, namely the tyrosine sulphation at the N-terminus of PSGL-1 was identified as being crucial for the binding of PSGL-1 to EV71 and for viral replication in lymphocytes ([@B104]). Some EV71 subgroups do not utilize PSGL-1 as a receptor to enter immune cells, as they cannot bind to the receptor. Only viruses with a G or Q amino acid at residue 145 of the structural protein VP1 can bind to PSGL-1 ([@B60]).

Mouse L929 cells that normally do not support EV71 infections, became highly infected with EV71 after being transfected and overexpressed with either SCARB2 or PSGL-1 ([@B152]). Although the L-SCARB2 cells were shown to be more susceptible to EV71 infection than L-PSGL-1 cells, they bound with a lower amount of EV71 when compared with the L-PSGL-1 cells. This indicates that the binding ability of the receptor does not determine the infection efficiency of said receptor ([@B152]).

Infection and Immunity
======================

As there is currently no effective treatment available for EV71, understanding virus--host interactions in greater detail will provide an increased knowledge base for the successful development of medical countermeasures ([@B107]).

The innate immune response is one of the body's earliest ways of fighting off pathogens ([@B133]). This immune response uses specific receptors that can recognize diverse foreign moieties and then launch an immune response to try and limit the infection ([@B133]). The innate immune response is much less specific than the adaptive immune response, but much more rapid and reacts instantaneously upon the discovery of pathogens. The first line of defense contributes by effectively limiting the infectivity of a pathogen, as well as activating the adaptive immune response to help destroy and clear the pathogenic organism ([@B133]).

Host cells, both immune and non-immune contain innate receptors called pattern-recognition receptors (PRRs), which can recognize materials/molecules of pathogens, and components of cell damage/death. These PRRs recognize the pathogens via the detection of pathogen associated molecular patterns (PAMPS) ([@B98]). PRRs can also recognize molecules from stressed/dying cells, named danger associated molecular patterns (DAMPs) and launch a response ([@B136]). The main receptors of viral PAMPs are toll-like receptors (TLRs), nucleotide oligomerization domain (NOD) like receptors (NLRs) and retinoic acid inducible gene I (RIG-I) like receptors (RLRs) ([@B41]).

Innate Immunity against EV71
----------------------------

Enterovirus 71 is mainly detected via the RLRs; RIG-I, melanoma differentiation-associated protein 5 (MDA5), and TLR3 ([@B110]). The binding of EV71 to the RLRs sets off a signaling cascade activating mitochondrial antiviral-signalling protein (MAVS). MAVS associates with tumour necrosis factor (TNF) receptor associated factor 3 (TRAF3), recruiting TANK-binding kinase 1 (TKB1) and IκB kinase, leading to the phosphorylation of interferon regulatory factors 3 and 7 (IRF-3 and IRF-7) ([@B35]). This phosphorylation causes these two IRF molecules to dimerise, causing the formation of hetero- and homodimers, which translocate to the nucleus and bind to interferon stimulate response elements (ISREs). This leads to the expression of type I interferon genes ([@B35]). MAVS activates NF-κB through a caspase 8/10 dependent pathway ([@B142]). TLR3 also activates NF-κB by inducing Interferon- β (IFN-β), which associates with receptor-interacting protein 1 (RIP1), activating NF-κB. This coordinated network activates many pro-inflammatory cytokines, chemokines, enzymes, and adhesion molecules to fight the pathogen ([@B70]).

Interferons (IFN's) are molecules that are vital to the body's immune response in order to help control virus replication and spread ([@B65]). Based on the interaction they have with their receptors, they have been categorized into three groups; type I, type II, and type III. Both type I and type III IFNs have been suggested to play vital roles in the defense against viral infections ([@B119]). Specific interferon-α (IFN-α; a type I IFN molecule produced by leukocytes) subtypes have been shown to be inhibitors of EV71 infection (IFN-α4, 6, 14, and 16) ([@B159]). Unfortunately, IFNs have only been shown to be effective as pre-treatments as *in vivo* and patient studies suggest that IFN's offer little help as a treatment after contraction of the virus ([@B85]).

Viral proteases are vital for the processing of most viral polyproteins. EV71 relies on its two proteases, 2A and 3C, to cleave viral protein precursors into their functional forms (**Figure [2](#F2){ref-type="fig"}**; [@B76]). These proteases not only cleave viral proteins, they can also cleave host proteins to aid in immune evasion ([@B128]). Viral protease 2A has been shown to cleave MDA5, the main cellular receptor for detecting EV71 infection (**Table [1](#T1){ref-type="table"}**). This cleavage diminishes the production and activation of IRF3 and IFN type I ([@B32]). The EV71 protease 2A can also cleave MAVS at several sites which again leads to the disruption of IRF3 phosphorylation and a decrease in type I IFN production, leading to increased EV71 propagation, compared to if the response was active ([@B142]). Data has been presented that suggests 2A interferes with IFNAR I by reducing its expression ([@B89]). The reduction in IFNAR I expression has been postulated as why exogenous IFN has had limited effect as a treatment ([@B99]). However, this hypothesis is still contested by some ([@B86]), and more evidence will be needed to address this hypothesis.

###### 

Table showing the reported functions of the individual EV71 proteins on virus and host.

  Protein   Function
  --------- --------------------------------------------------------------------------------------------------------------
  VP1-3     Structural proteins, form icosahedral capsid. 60 copies of pseudo *T* = 3 symmetry
  VP4       Structural protein, lies on the inside of the capsid, implicated in viral genome release
  2A        A protease, important for viral polyprotein and host protein cleavage
  2B        A viroporin, creates pores in the host ER
  2C        Induces structural rearrangements, not too much known about this protein.
  3A        Localizes viral replication complexes to vesicle membrane surfaces
  3B        Viral protein genome-linked (VPg)
  3C        A protease, cleaves viral precursor proteins as well as host proteins such as retinoic acid inducible gene I
  3D        RNA Polymerase, replicates viral RNA

Inhibition of the host interferon response has also been shown by the 3C protease ([@B69]). 3C interacts with the N-terminal domain of RIG-I preventing the interaction with MAVS and leading to a decrease in IRF3 and IFN (**Table [1](#T1){ref-type="table"}**; [@B69]). Similarly EV71 3C has been shown to bind and degrade IRF 9 ([@B56]) and to cleave IRF 7 ([@B71]) impairing the ability of these two cellular proteins to stimulate the production of ISGs and IFN.

EV71 and Host Replication Factors
---------------------------------

The genome of EV71 is uncapped and therefore initiation of translation by ribosomes are facilitated by the presence of a type I internal ribosome entry site (IRES) ([@B77]). This tertiary RNA structure is a common feature at the 5′ end of picornaviruses. Initiation of translation at an IRES requires specific cellular proteins and their absence can lead to inefficient IRES-dependent translation. During EV71 and general picornavirus infection, host cell factors, known as IRES transacting factors (ITAFs), involved in the initiation of cap-dependent translation on host mRNAs are degraded by viral proteases ([@B128]). Thus, inhibiting cap-dependent host cell translation and facilitating the translation of viral genomes (which act as an mRNA) ([@B113]). During viral infection, EV71 expresses viral protease 2A that cleaves eIF4G, part of the eukaryotic initiation factor 4F complex (eIF4F) needed for cap dependent translation. Although these results in a significant decrease in the hosts capped mRNA translation, it increases the translation efficiency of the EV71 IRES (**Table [1](#T1){ref-type="table"}**; [@B139]).

Some novel ITAFs for EV71 have also been discovered. Far upstream element binding protein 1 and 2 (FBP1 and 2) have both been identified as novel ITAFs for EV71 ([@B53]; [@B20]). FBP1 enhances the replication activity of the virus and IRES-dependent translation. FBP2, however, has been shown to be a negative regulator of IRES activity, by out competing the positive ITAF hnRNP1 ([@B77]). However, EV71 infection triggers proteasomal, autophagic, and caspase activity mechanisms of the host cell, which cleave FBP2, and these cleavage fragments transform FBP2's function from a negative regulator to a positive promoter (**Table [1](#T1){ref-type="table"}**; [@B53]; [@B20]).

Enterovirus 71's ability to interrupt, intercept and disrupt the host immune response is critical to the survival and propagation of the virus, and whilst this has a negative effect for the patients, it gives an insight into possible areas that could be targeted to disrupt virus biology.

Deciphering Pathophysiology Using *in Vitro* and *in Vivo* Models
=================================================================

*In Vitro* Cellular Models
--------------------------

*In vitro* models whilst being the initial "go to" model for viral experiments, can come in many different forms and serve many different purposes. The most basic of these are isolation and viral kinetics, for which rhabdomyosarcoma (RD) cells are the most utilized for EV71 ([@B112]). One major advantage of *in vitro* cellular models is that they can be adapted and modified very easily. This aids the discovery of important proteins and cellular functions that would otherwise be extremely difficult. The EV71 cellular receptor, SCARB2 was identified utilizing *in vitro* techniques. Mouse L929 cells, not known to be targeted by EV71 were first transfected with RD cell genomic DNA and then infected with EV71. Transcriptomics analysis on highly infected cells identified SCARB2 as the receptor responsible for this new ability to become infected ([@B153]). PSGL-1 was discovered using Jurkat cells, an immortalized T cell line ([@B103]). A retroviral cDNA library from EV71 susceptible Jurkat cells was generated and then used for expression cloning. Transduction of P3U1 produced four colonies that bound to EV71 coated dishes, which all encoded PSGL-1 ([@B103]). Without this *in vitro* model, this discovery may not have occurred as *ex vivo* primary T cells do not proliferate, and therefore this type of experiment would not have been feasible.

Another advantage of using cell lines is they can provide lines that are not always readily available as primary cells. Primary human monocytes and T cells often not easily accessible due to availability or ethics, however, with *in vitro* cell lines such as THP-1 (monocytes) or Jurkat (T cells) these issues can be easily over come. THP-1 cells have been used to show the role of NLRP3 inflammasome activation and IL-1β maturation during interaction with the EV71 protein 3D ([@B147]).

*Ex Vivo* Models
----------------

Whilst they are not always readily accessible, primary *ex vivo* models can be of huge benefit to investigations as they bridge the gap between immortalized *in vitro* cell lines and *in vivo* animal models. They provide insights into how the body might react to an infection without any chance of harm to the host. Understanding EV71's ability to infect immune cells and their possible role in EV71 severity and fatalities was not always clear. However, using *ex vivo* models allowed studies to investigate the direct effect EV71 has on these immune cells and any indirect downstream effects ([@B19]). EV71 was shown to directly infect monocytes and lymphocytes from freshly isolated blood mononuclear cells (PBMCs) and induce the production of proinflammatory cytokines such as TNF-α and MIF during the course of an infection ([@B19]). *Ex vivo* models have been used to show how the activation of JNK1/2 and p38 MAPK pathways can promote EV71 infection in dendritic cells (DCs) ([@B111]).

*In Vivo* Animal Models
-----------------------

Interestingly, *in vivo* mouse models of EV71 have demonstrated an age-dependent susceptibility to the virus ([@B4]; [@B26]; [@B61]; [@B39]). Non-transgenic, immunocompetent mice are resistant to EV71 infection once they are past the weaning stage, regardless of the route of infection ([@B4]; [@B26]; [@B61]; [@B39]). In an effort to develop a EV71 mouse model more similar to the onset of human disease, mouse-adapted EV71 strains have been generated that are capable of infecting mice via the oral route, and can cause neuropathology in the brainstem and spinal cord as well as paralysis of the rear limbs ([@B23]; [@B148]; [@B105]). However, these models still have an age limitation and do not cause the onset of disease after the mice reach 14 days old ([@B23]; [@B148]; [@B105]). Whilst these models are not ideal due to their age-limiting factor, they have still proven to be useful tools in the examination of EV71 pathogenesis. This model was used in the discovery of type I interferon being an essential innate defense mechanism in the controlling or EV71 infection and that EV71 tries to avoid this mechanism by inhibiting type I interferon through its 3C protease ([@B85]; [@B68]).

To get around this age limitation, immunocompromised models such as NOD/SCID ([@B4]) and AG129 ([@B61]) mice have been used which cause similar features and symptoms seen in the immunocompetent mouse models but in older mice ([@B4]; [@B61]). Whilst this is an advantage, it also has its drawbacks, namely immunocompromised mice stray further from the human model they are trying to replicate and thus give us a less reliable report on what may be causing these symptoms in humans ([@B130]). Although a more recent study could replicate skin rash induced by EV71 infection in the NOD/SCID mouse model ([@B75]).

Transgenic mice containing the human EV71 receptors SCARB2 and PSGL-1 have been generated and been shown to be infected with EV71 to varying degrees ([@B84]; [@B39]). Mice expressing the PSGL-1 gene are only susceptible to mouse-adapted strains of EV71, and whilst this model exhibited symptoms that were similar to those seen in wild-type mice, these mice suggest that PSGL-1 cannot provoke EV71 infectivity in mice on its own ([@B84]). Transgenic mice that express the human SCARB2 in their CNS neurons, lung pneumocytes, hepatocytes, and intestinal epithelium (i.e., similar profile to humans) have been shown to be susceptible to infection by EV71 after they are 6 weeks of age. These mice display symptoms of neurotropism, neuropathology, ataxia, paralysis, and death, which are similar to symptoms seen in humans ([@B39]).

To try and replicate the human disease model, mice have been orally infected with EV71 with differing degrees of effectiveness. Non-adapted virus strains have been shown to cause skin lesions in immunocompetent neonatal mice, but other than this symptom, animals typically continued to grow normally with no neurological effects ([@B23]). However, mouse-adapted strains have been shown to not only cause skin lesions but also movement disorientation, hind limb paralysis followed by death ([@B23]). When using immunocompromised mice, orally infected non-adapted virus was capable of causing neurological complications and death ([@B61]; [@B75]). Whilst this route is much closer to the natural route of infection then intra-spinal, cranial or peritoneal injections, these are still very young mice and do not represent the same respective age that the disease affects humans. These mice are still fed by their mothers, at this stage in human development children are still protected by maternal antibodies passed through passive transfer ([@B49]) and breast milk ([@B45]), therefore much less susceptible to the disease.

Non-human primates have been shown to be susceptible to EV71 infection and have since been used in various studies ([@B101], [@B100]). Cynomolgus monkeys show very similar neurological manifestations of symptoms when infected intraspinally or intravenously, including acute flaccid paralysis, ataxia and encephalitis. The animals also presented with a broad viral circulation including spinal cord, cerebrum, brainstem, and CNS ([@B101], [@B100]). However, they do not suffer from blisters or lesions on the skin, nor do they suffer from pulmonary oedema ([@B101], [@B100]). A Rhesus monkey model has also been used to assess EV71 infection. These monkeys also develop CNS infections after intracranial, intravenous, intratracheal or orally given virus. Tissue damage and cellular infiltrates in the lungs were noted in these monkeys, they were not observed in the spleen or pancreas, which also show high viral load. Although these monkeys did not show vesicular lesions on the skin or typical neurological symptoms, half of them did suffer from pulmonary oedema when infected intracranially ([@B164]). This is the first model to show this symptom outside of humans, however, it is not known if the pulmonary oedema is due to CNS damage and inflammation or if it is a consequence of viral cytolysis in the lungs ([@B164]).

Whilst there are many advantages that come with using animal models, there are also some drawbacks. One issue is the use of animal-adapted viruses. EV71 mouse models are very limited by the age of the mouse. To circumvent this, mouse-adapted EV71 strains are used. As EV71 is a positive sense single stranded RNA virus it can evolve quickly through mutations due to the lack of proofreading mechanisms ([@B31]). All viruses will contain quasi-species that will continue to be introduced with multiple passages during animal species adaptation. These mutations can cause significant differences to the virus, such as structural changes ([@B26]) and alterations in the host--virus interactions that differ from the wild-type strain ([@B26]). The mutation of G145E in the VP1 protein of EV71 has been shown to increase the level of morbidity and mortality during EV71 infection in mice ([@B26]; [@B54]).

Whilst these animal models are not perfect representations of the disease or the route it takes in humans, they still provide us with lots of crucial information on the role of the virus and of the host immune response. Notably, a significant study recently reported the generation of a hybrid mouse model by cross-breeding between STAT-1 KO and hSCARB2 transgenic mice. This model was able to support efficient lower titer (1 million pfu/mouse) EV71 experimental infection using older mice. Therefore, this hybrid model lends a strong support to the importance of both entry factor and host innate immunity ([@B83]).

Potential Therapeutics for EV71
===============================

Antivirals
----------

Many drugs that have been already developed and used to fight other picornaviruses, such as polioviruses and rhinoviruses, were tested for their abilities to limit EV71 infection. These drugs, ribavirin ([@B74]; [@B161]), pleconaril ([@B121]; [@B161]) and rupintrivir ([@B163]) have all shown some sort of protective antiviral effect in mouse models. However, it remains to be seen how this would be translated to human infections. Also as the EV71 genome is synthesized through the virus's 3D polymerase ([@B87]), which lacks a proofreading activity, mutations frequently arise and could quickly lead to the generation of antiviral resistant viruses ([@B21]).

The recent discovery of the crystal structure of EV71 ([@B115]) has shed some insights into possible drug targets for future antivirals against EV71. The resolution of this structure by x-ray crystallography showed the presence of a hydrophobic pocket factor located underneath a depression known as the canyon. It has been postulated that the binding of molecules to this pocket region could stabilize the capsid and therefore inhibit the uncoating process induced by the EV71 receptor ([@B115]). Several compounds have been created which bind to this pocket region and showed effective *in vitro* inhibition of EV7 ([@B126]; [@B25]; [@B127]; [@B12]; [@B22]; [@B116]). However, just a single point mutation was enough to confer resistance against this type of compound ([@B129]).

Type I IFN, has been shown as an effective antiviral to treat viral infections such as HCV ([@B120]), so experiments were done to investigate IFNs ability as an EV71 therapeutic. Studies have shown in both *in vivo* ([@B85]) and *in vitro* ([@B159]) systems that IFN could increase the survival rate and reduce EV71 replication ([@B85]; [@B159]). However, the viral proteases 2A and 3C have the ability to degrade IFN and the IFN antiviral pathway and may lead to the reduction in expression of interferon-α/β receptor (IFNAR) ([@B99]; [@B69], [@B71]; [@B142]; [@B32]). There have been reports of synergistic effects when 3C inhibitors and IFN are combined ([@B56]), but this would have to be combined with a 2A inhibitor to further inhibit the interruption and degradation of IFN.

Monoclonal Antibodies
---------------------

As there is no current antiviral treatment, and vaccine development, whilst currently underway, is not fully approved outside of China, human IVIG has been used on a presumptive basis as a last resort ([@B17]). This treatment has perceived positive benefits, possibly through modulatory properties or viral neutralization, but is not wholly effective and has not been tested via a randomized controlled trial. IVIG also poses a potential risk of infection via other pathogens. Humanized mouse monoclonal antibodies eliminate this risk whilst increasing the specificity against the virus. Humanized mouse monoclonal antibodies against other viruses such as RSV have already been approved by the FDA ([@B138]; [@B33]).

There have been several studies that suggest that monoclonal antibodies could be an effective treatment against EV71 infection, and multiple sites on the virus have been found as possible targets. [@B114] raised two antibodies against an empty immature EV71 particle in mice. The structure of this particle, which is similar to the "A" particle seen when EV71 recognizes a host cell before genome release, differs from that of a mature virus. These antibodies were shown to neutralize EV71 *in vitro* by instigating a conformational change after incubation with the mature virus, transforming the infectious virus into an "A" particle and instigating genome release ([@B114]).

Another antibody, produced against the EV71 virus like particle (VLP) showed potent neutralizing capabilities *in vitro* ([@B66]). It was later discovered that the antibody bivalently bound across the twofold axis of the EV71 virion, potentially preventing the conformational changes in viral capsid proteins required for viral genome release ([@B158]).

Antibodies raised in mice against a conserved VP3 knob region have shown protective neutralizing effect across the different subgroups of EV71 ([@B62]). Whilst both antivirals and monoclonal antibodies remain important tools to fight EV71 infection, a vaccine still serves as our best chance at eradicating this virus, as shown with the almost total eradication of polio after the introduction of the Salk and Sabin vaccines ([@B117]).

Vaccines
--------

After the success of the polio vaccines, it was envisioned that EV71, closely related to polio, would also be an easy target for near eradication via a vaccine. Studies in mice demonstrated that the transfer of antiserum provided protection against EV71, further indicating the attainability of a vaccine ([@B160]). EV71 vaccine candidates have been suggested in many different forms; from attenuated strains ([@B5]), inactivated whole virus ([@B167]), and VLPs ([@B29]) to recombinant proteins ([@B143]) and peptide vaccines ([@B38]).

Live attenuated vaccines have been tested in cynomolgus monkeys and these induced the production of high levels of neutralizing antibodies that provided cross protection across the sub groups ([@B95]). However, as with all live attenuated vaccines, there is the possibility for the virus to mutate and cause disease. One study showed a vaccine candidate producing mild neurological symptoms and being neurotropic when injected intravenously ([@B5]).

DNA vaccines have been attempted for EV71. However, DNA constructs containing EV71 VP1 gene that elicited specific VP1 immunoglobulin G's (IgG's) and neutralizing antibodies conferred low levels of antigenicity ([@B141]).

Inactivated whole virus vaccines have been shown in mouse models of EV71 to produce very high levels of virus specific antibodies that are cross neutralizing ([@B149]; [@B106]). These successful pre-clinical studies lead the way for phase I ([@B73]) and phase II ([@B165]) clinical trials, and since then three vaccines have moved on to phase III clinical trials, all from China and based on the C4 strain ([@B166], [@B165]; [@B72]). These trials involved over 30,000 children and resulted in the prevention of 90% of HFMD and 80% of other EV71 related symptoms, and the Chinese FDA has approved two of these vaccines. Although these vaccines have only been approved in China, this is a very exciting prospect in the eradication of EV71. However, there is still work to be done on antiviral treatment and therapies for the treatment of patients and to help unravel the mechanisms behind this disease.

Conclusion
==========

There have been major breakthroughs in EV71 research in the last couple of decades: from the identification of host receptors, to the discovery of molecular mechanisms of virus--host interactions, to the phase III trials for vaccines. Although there is an understanding of EV71 pathogenesis, many areas of uncertainty remain with many mechanisms still not well understood and many pathways that have yet to be proven functionally. There is still a need for an animal model that better mimics the human disease. The development of such models will enable us to gain a much better understanding of the path of EV71 infection, and may give us an insight in to new molecular mechanism that we can target to interrupt the virus and stop the infection.

Author Contributions
====================

JC searched the literature and compiled and wrote the review. LN helped design, write, and edit the review. JH, TS, and M-HO helped to write, edit, and critique the review.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

JC was funded by an Institute of Global Heath, University of Liverpool scholarship and the A^∗^STAR Research Attachment Program (ARAP) scholarship during the writing of this review.

[^1]: Edited by: *John W. A. Rossen, University Medical Center Groningen, Netherlands*

[^2]: Reviewed by: *Chiaho Shih, Academia Sinica, Taiwan; Haider Abdul-Lateef Mousa, University of Basrah, Iraq*

[^3]: This article was submitted to Infectious Diseases, a section of the journal Frontiers in Microbiology
